Replicor's Groundbreaking HBV/HDV Treatment Shows Promise in Compassionate Access Program Replicor Inc.'s latest report details the successful outcomes of its compassionate access program for chronic HBV/HDV patients using REP 2139-Mg.

Replicor's Groundbreaking HBV/HDV Treatment Shows Promise in Compassionate Access Program #Canada #Montreal #Replicor #HBV #HDV

@HepDART dr. Vaillant: ALT flares during #HBsAg reduction to 1 IU/ml w/ Nucleic Acid polymers (NAP) +PegIFN therapy predict functional cure of #HBV #hepdart #replicor